{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:06:48Z","timestamp":1791176808152,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We have previously demonstrated that an anti-CD19 monoclonal antibody (MAb; HD37) inhibits the function of the P-glycoprotein (P-gp) pump in a multidrug-resistant (MDR) B-lymphoma cell line, Namalwa\/MDR1, and that this effect is not due to the recognition of a cross-reactive epitope on P-gp. In this study, we have used the same cell line to define the mechanisms responsible for the effect of HD37 on the P-gp pump. Using fluorescence resonance energy transfer (FRET), we show that CD19 and P-gp are constitutively associated in cells. In the absence of treatment with anti-CD19, 40% of P-gp molecules expressed by Namalwa\/MDR1 cells reside in the low-density lipid (ie, cholesterol-rich) microdomains (lipid rafts). Following treatment of the cells with HD37 and disruption of the interactions between P-gp and CD19, P-gp translocated out of lipid rafts and CD19 translocated into lipid rafts. The effect of chemosensitization on Namalwa\/MDR1 cells was specific for CD19; an anti-CD22 MAb had no such effect, although the cells express CD22. These results suggest that anti-CD19 might chemosensitize P-gp+ cells by interfering with interactions between CD19 and P-gp, rapidly resulting in the translocation of P-gp into a compartment on the plasma membrane where it is no longer active.<\/jats:p>","DOI":"10.1182\/blood-2003-12-4255","type":"journal-article","created":{"date-parts":[[2004,3,9]],"date-time":"2004-03-09T01:13:44Z","timestamp":1078794824000},"page":"178-183","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line"],"prefix":"10.1182","volume":"104","author":[{"given":"Maria-Ana","family":"Ghetie","sequence":"first","affiliation":[{"name":"From the Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Marches","sequence":"additional","affiliation":[{"name":"From the Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kufert","sequence":"additional","affiliation":[{"name":"From the Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen S.","family":"Vitetta","sequence":"additional","affiliation":[{"name":"From the Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021215381205100_REF1","doi-asserted-by":"crossref","unstructured":"Gottesman MM, Pastan I. Biochemistry of multi-drug-resistance mediated by the multi-drug transporter. Ann Rev Biochem. 1993;62: 385-427.","DOI":"10.1146\/annurev.bi.62.070193.002125"},{"key":"2020021215381205100_REF2","doi-asserted-by":"crossref","unstructured":"Borst P. Multidrug resistant proteins. Semin Cancer Biol. 1997;8: 131-134.","DOI":"10.1006\/scbi.1997.0072"},{"key":"2020021215381205100_REF3","unstructured":"Germann UA. P-glycoprotein: a mediator of multi-drug resistance in tumour cells. Proc Natl Acad Sci U S A. 1996;83: 7785-7789."},{"key":"2020021215381205100_REF4","doi-asserted-by":"crossref","unstructured":"Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A. 1986;83: 7785-7789.","DOI":"10.1073\/pnas.83.20.7785"},{"key":"2020021215381205100_REF5","doi-asserted-by":"crossref","unstructured":"Mechetner EB, Roninson I. Efficient inhibition of P-glycoprotein-mediated multi-drug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A. 1992;89: 5824-5828.","DOI":"10.1073\/pnas.89.13.5824"},{"key":"2020021215381205100_REF6","doi-asserted-by":"crossref","unstructured":"Mechetner EB, Schott B, Morse BS, et al. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci U S A. 1997;94: 12908-12913.","DOI":"10.1073\/pnas.94.24.12908"},{"key":"2020021215381205100_REF7","doi-asserted-by":"crossref","unstructured":"Fisher G, Lum B, Hausdorff J, Sikic BI. Pharmacological consideration in the modulation of multi-drug resistance. Eur J Cancer. 1996;32: 1082-1088.","DOI":"10.1016\/0959-8049(96)00111-6"},{"key":"2020021215381205100_REF8","doi-asserted-by":"crossref","unstructured":"Ghetie MA, Picker LJ, Richardson JA, et al. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood. 1994;83: 1329-1336.","DOI":"10.1182\/blood.V83.5.1329.1329"},{"key":"2020021215381205100_REF9","unstructured":"Ghetie MA, Ghetie V, Vitetta ES. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug resistant B lymphoma cells. Clin Cancer Res. 1999;5: 3920-3927."},{"key":"2020021215381205100_REF10","doi-asserted-by":"crossref","unstructured":"Chambers TC, McAvoy EM, Jacobs JW, Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem. 1990;265: 7679-7685.","DOI":"10.1016\/S0021-9258(19)39168-9"},{"key":"2020021215381205100_REF11","doi-asserted-by":"crossref","unstructured":"Hardy SP, Goodfellow HR, Valverde MA, et al. Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J. 1995;14: 68-75.","DOI":"10.1002\/j.1460-2075.1995.tb06976.x"},{"key":"2020021215381205100_REF12","doi-asserted-by":"crossref","unstructured":"Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A. 2002;99: 10347-10352.","DOI":"10.1073\/pnas.162366399"},{"key":"2020021215381205100_REF13","doi-asserted-by":"crossref","unstructured":"Luker G, Pica C, Kumar A, Covey D, Piwnica-Worms D. Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. Biochemistry. 2000;39: 7651-7661.","DOI":"10.1021\/bi9928593"},{"key":"2020021215381205100_REF14","doi-asserted-by":"crossref","unstructured":"Lavie Y, Fiucci G, Liscouitch M. Upregulation of caveolar and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem. 1998;273: 32380-32383.","DOI":"10.1074\/jbc.273.49.32380"},{"key":"2020021215381205100_REF15","doi-asserted-by":"crossref","unstructured":"Demeule M, Jodoin J, Gingras D, Beliveau R. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett. 2000; 466: 219-224.","DOI":"10.1016\/S0014-5793(00)01087-5"},{"key":"2020021215381205100_REF16","doi-asserted-by":"crossref","unstructured":"O'Connor R, Liu C, Ferris CA, et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood. 1995;86: 4286-4294.","DOI":"10.1182\/blood.V86.11.4286.bloodjournal86114286"},{"key":"2020021215381205100_REF17","doi-asserted-by":"crossref","unstructured":"Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol. 2000; 1: 156-159.","DOI":"10.1038\/77842"},{"key":"2020021215381205100_REF18","doi-asserted-by":"crossref","unstructured":"Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol. 1996; 27: 251-255.","DOI":"10.1016\/0306-3623(95)02013-6"},{"key":"2020021215381205100_REF19","doi-asserted-by":"crossref","unstructured":"Ferte J. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem. 2000;267: 277-294.","DOI":"10.1046\/j.1432-1327.2000.01046.x"},{"key":"2020021215381205100_REF20","doi-asserted-by":"crossref","unstructured":"Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455: 152-162.","DOI":"10.1016\/0005-2736(76)90160-7"},{"key":"2020021215381205100_REF21","doi-asserted-by":"crossref","unstructured":"Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity. 1997;6: 107-118.","DOI":"10.1016\/S1074-7613(00)80418-5"},{"key":"2020021215381205100_REF22","doi-asserted-by":"crossref","unstructured":"Cherukuri A, Cheng PC, Sohn HW, Pierce SK. The CD19\/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity. 2001;14: 169-179.","DOI":"10.1016\/S1074-7613(01)00098-X"},{"key":"2020021215381205100_REF23","doi-asserted-by":"crossref","unstructured":"Bradbury LE, Goldmacher VS, Tedder TF. The CD19 signal transduction complex of B lymphocytes. J Immunol. 1993;151: 2915-2927.","DOI":"10.4049\/jimmunol.151.6.2915"},{"key":"2020021215381205100_REF24","doi-asserted-by":"crossref","unstructured":"Matsumoto AK, Martin DR, Carter RH, Klickstein LB, Ahearn JM, Fearon DT. Functional dissection of the CD21\/CD19\/TAPA-1\/Leu-13 complex of B-lymphocytes. J Exp Med. 1993;178: 1407-1417.","DOI":"10.1084\/jem.178.4.1407"},{"key":"2020021215381205100_REF25","doi-asserted-by":"crossref","unstructured":"Tsitsikov EN, Gutierrez-Ramos JC, Geha RS. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc Natl Acad Sci U S A. 1997;94: 10844-10849.","DOI":"10.1073\/pnas.94.20.10844"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/1\/178\/1699498\/zh801304000178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/1\/178\/1699498\/zh801304000178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T02:39:36Z","timestamp":1682649576000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/1\/178\/114387\/An-antiCD19-antibody-inhibits-the-interaction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-12-4255","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,1]]}}}